ArticleFrontiers in medicine2026
Predictors of ≥50% volume reduction after radiofrequency ablation of uterine fibroids: a single-center retrospective case series in Romania.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Study objective: The study aimed to explore the potential of routinely collected pre-procedural clinical and ultrasonographic parameters (age, classification, baseline fibroid volume, and baseline Doppler score) in predicting treatment response following transvaginal radiofrequency ablation (RFA). We employed a combined machine learning-based feature ranking and regression interpretability approach to provide a proof-of-concept for future data-driven predictive models. Design: This study was designed as a single-center retrospective case series. Setting: The study was conducted at a public hospital in Romania, where RFA was introduced as a minimally invasive alternative for uterine fibroid treatment. Patients: Twenty-two fibroids were treated in women aged 28-52 years (mean age 38), who were selected based on the presence of symptoms or documented fibroid growth. Interventions: Transvaginal ultrasound-guided radiofrequency ablation was performed using the VIVA RF system. Baseline and post-procedural measurements included fibroid size and volume, vascularity as measured by Doppler score, and anatomical classification according to FIGO criteria. Measurements and main results: Fibroid volume decreased from a mean of 60.82 cm Conclusion: This proof-of-concept study demonstrates the potential of using routinely collected pre-procedural data for predictive analytics in RFA of uterine fibroids. The successful outcomes observed in two submucosal fibroids (G0 and G1) suggest that RFA followed by hysteroscopic myomectomy may serve as a viable two-step fertility-preserving treatment approach. However, the small sample size and class imbalance highlight the critical need for larger, prospective, multicentric studies to develop clinically valid predictive models for minimally invasive fibroid treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.